ストックスクリーナーアプリを入手
7.72
3.90%
0.29
アフターアワーズ：
7.53
-0.19
-2.46%
前日終値:
$7.43
開ける：
$7.54
24時間の取引高:
3.53M
Relative Volume:
1.40
時価総額：
$1.25B
収益：
$246.03M
当期純損益:
$-32.00M
株価収益率:
-36.33
EPS:
-0.2125
ネットキャッシュフロー:
$-16.78M
1週間 パフォーマンス:
-22.02%
1か月 パフォーマンス:
-3.38%
6か月 パフォーマンス:
+54.09%
1年 パフォーマンス:
+122.48%
1日の値動き範囲:
$7.22
$7.75
1週間の範囲:
$7.00
$10.08
52週間の値動き範囲:
$2.82
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.72 | 1.23B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-12 | 再開されました | H.C. Wainwright | Buy |
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentalsTrade Entry Summary & Reliable Trade Execution Plans - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsWeekly Earnings Recap & Community Verified Trade Signals - newser.com
Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stock2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Will Xeris Biopharma Holdings Inc. stock deliver long term returnsJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - newser.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
Q4 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript - Insider Monkey
Xeris raises 2025 revenue guidance to $285M-$290M as RECORLEV revenue more than doubles year-over-year - MSN
Xeris Biopharma Holdings, Inc. (2B30.F) stock price, news, quote and history - Yahoo Finance Singapore
Xeris Biopharma Hits Day Low at $7.00 Amid Price Pressure - Markets Mojo
How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.Earnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
Xeris Biopharma Holdings Inc (XERS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.2025 Year in Review & Verified Stock Trade Ideas - newser.com
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - BioSpace
Assessing Xeris Biopharma (XERS) Valuation Following Strong Q3 Earnings and Raised Revenue Guidance - simplywall.st
Xeris Biopharma Reports Strong Q3 2025 Financial Results - TipRanks
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say - sharewise.com
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 - sharewise.com
Xeris Biopharma Holdings Inc (XERS) Q3 2025 Earnings Call Highli - GuruFocus
Is a relief rally coming for Xeris Biopharma Holdings Inc. holders2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Xeris Biopharma Holdings, Inc. Updates Earnings Guidance for the Full-Year 2025 - MarketScreener
Transcript : Xeris Biopharma Holdings, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Xeris Biopharma Shares Fall After Reporting Breakeven Q3, Revenue Increase; 2025 Revenue Outlook Raised - MarketScreener
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript - AOL.com
Xeris Biopharma Q3 2025 Earnings Call Transcript - MarketBeat
Q3 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma Holdings Inc (XERS) Q3 2025 Earnings: EPS of $0. - GuruFocus
Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0, vs. FactSet Est of $0 - MarketScreener
[8-K] Xeris Biopharma Holdings, Inc. Reports Material Event | XERS SEC FilingForm 8-K - Stock Titan
Xeris Q3 product revenue slightly misses; updates 2025 revenue guidance - MarketScreener
Xeris Pharmaceuticals stock hits 52-week high at $10.03 By Investing.com - Investing.com South Africa
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendationsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
What high frequency data says about Xeris Biopharma Holdings Inc.Market Trend Summary & High Accuracy Swing Trade Signals - newser.com
Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Why Xeris Biopharma Holdings Inc. stock is favored by top institutionsQuarterly Investment Review & Comprehensive Market Scan Reports - fcp.pa.gov.br
Xeris Pharmaceuticals stock hits 52-week high at $10.03 - Investing.com India
How Xeris Biopharma Holdings Inc. stock responds to policy changesMarket Performance Summary & Capital Efficiency Focused Strategies - Fundação Cultural do Pará
Is Xeris Biopharma Holdings Inc. stock undervalued vs historical averagesWeekly Trend Summary & AI Enhanced Market Trend Forecasts - newser.com
40,465 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Savvy Advisors Inc. - MarketBeat
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
1.40%
大文字化:
|
ボリューム (24 時間):